Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC

by Paola Cravero, MD, Nuno Vaz, MD, Biagio Ricciuti, MD, Sarah E. Clifford, MPH, Gianluca DiUbaldi, BS, BA, Dawn Drevers, RN, Kaitlin Morton, BS, Rebecca E. Rivenburgh, BS, Mizuki Nishino, MD, MPH, Mark M. Awad, MD, PhD
Published 2020-11-01

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

by Biagio Ricciuti, MD, Abdul Rafeh Naqash, MD, Jarushka Naidoo, MD, Kartik Sehgal, MD, Adam Miller, MD, Kenneth Kehl, MD, MPH, Deepti Venkatraman, MPH, Jacob Sands, MD, Giuseppe Lamberti, MD, Gonzalo Recondo, MD, PhD, Jiajia Zhang, MD, Shravanti Macherla, MD, Sameer Baig, MD, Paul Walker, MD, Deepa Rangachari, MD, Justin F. Gainor, MD, Daniel B. Costa, MD, Naiyer Rizvi, MD, Lynette M. Sholl, MD, Mizuki Nishino, MD, MPH, Brian Henick, MD, Anna F. Farago, MD, PhD, Mark M. Awad, MD, PhD
Published 2020-11-01